Other ·Emerging evidence ·Reviewed May 2026
A calming flavonoid found in chamomile. Popularized by neuroscientist Andrew Huberman as a sleep aid. Also has anti-cancer and neuroprotective research.
The bottom line
Evidence rating emerging. Most-documented uses: sleep quality, anxiety reduction, nad+ preservation. 20 sources indexed (1995–2025), with 8 interaction records on file.
Core mechanism
Binds to benzodiazepine sites on GABA-A receptors (mild anxiolytic and sedative without dependency). Inhibits CD38 in animal models (Escande 2013); no human clinical trials confirm this mechanism. Inhibits aromatase (reduces estrogen conversion). Activates apoptosis in cancer cells via p53 pathway.17,15
Take 30-60 minutes before bed; stacks well with magnesium and glycine
Dosing protocol
Bioavailability of free apigenin is poor. Chamomile and parsley extracts vary in apigenin content.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Apigenin Extract.
Assumes 50-100 mg/day. Vendor basis: Life Extension, NOW/iHerb, Vitacost, and Amazon marketplace; pure apigenin is usually costlier than chamomile blends. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
Apigenin content varies widely by plant variety, drying, and preparation, so food amounts are approximate.
What to test, the optimal window inside the conventional range, and how long a response takes.
Apigenin inhibits CD38 and xanthine oxidase in vitro; small human studies show modest uric acid reduction and possible NAD+ sparing effects.7,14
Bioavailability of free apigenin is poor; chamomile and parsley extracts vary in apigenin content. Pair with hsCRP if anti-inflammatory rationale.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Apigenin, the active flavonoid in chamomile, binds benzodiazepine receptor sites and may produce mild sedation that supports sleep continuity.6,8
Human data are limited and mostly from chamomile; start low and avoid combining with other sedatives.
Apigenin from chamomile binds benzodiazepine sites and may produce gentle anxiolytic and sedative effects that ease falling asleep.6,8
Evidence is preliminary; insomnia persisting beyond a few weeks should be evaluated by a clinician.
CD38 inhibitor that may spare NAD+; clinical effect on aging endpoints is unproven.1,2
Bioavailability of free apigenin is poor.
A flavonoid that binds benzodiazepine sites to produce mild relaxation, potentially easing the transition to an earlier bedtime.6,8
Mostly traditional and mechanistic evidence; expect a gentle effect at best and rely on melatonin timing and light exposure for actual phase advance.
Evidence-based stacks that include it, with the exact dose and timing each one uses.
Apigenin is a natural flavonoid that binds GABA-A benzodiazepine receptors, promoting sleep through a different mechanism than melatonin.
Recommendation: Andrew Huberman's sleep stack: 50mg apigenin + 0.5-2mg melatonin (optional) + magnesium for comprehensive sleep support.
Both promote relaxation and sleep through GABAergic and glutamate-modulating pathways.
Recommendation: Combine for a gentle, non-habit-forming sleep support stack.
Both promote relaxation and sleep through GABAergic and glutamate-modulating pathways.
Recommendation: Combine for a gentle, non-habit-forming sleep support stack.
Both promote relaxation and sleep through GABAergic and glutamate-modulating pathways.
Recommendation: Combine for a gentle, non-habit-forming sleep support stack.
Both promote relaxation and sleep through GABAergic and glutamate-modulating pathways.
Recommendation: Combine for a gentle, non-habit-forming sleep support stack.
Both promote relaxation and sleep through GABAergic and glutamate-modulating pathways.
Recommendation: Combine for a gentle, non-habit-forming sleep support stack.
NMN raises NAD+ substrate; apigenin inhibits CD38, the enzyme that consumes NAD+. Combined effect on whole blood NAD+ may be additive.
Recommendation: Combine for NAD+ optimization in longevity-focused stacks. Track NAD+ via specialty assays (Jinfiniti, ChromaDex) at baseline and 8 weeks.
Apigenin has benzodiazepine-receptor and GABA(A)-modulating activity in preclinical studies. One receptor study specifically found that apigenin enhanced diazepam's positive modulation of GABA(A) receptor activation. In people, this could mean more sedation, impaired coordination, or slowed reaction time, although direct clinical interaction trials are lacking.
Recommendation: Use apigenin cautiously if you take diazepam, especially when starting either product or increasing doses. Avoid alcohol and other sedatives, and do not drive until you know how the combination affects you. Stop apigenin and contact your prescriber if sedation, confusion, or balance problems increase.
Numbered references. Citations throughout the page link here.
Zhang N, Nao J, Dong X. Efficacy and Safety of Natural Apigenin Treatment for Alzheimer's Disease: Focus on In vivo Research Advancements. Current neuropharmacology. 2025
Systematic review documenting apigenin's anticancer mechanisms including induction of apoptosis, cell cycle arrest, and inhibition of tumor cell proliferation across multiple cancer types.
Systematic review of preclinical studies found apigenin exerted neuroprotective effects through anti-inflammatory, antioxidant, and anti-apoptotic mechanisms in models of neurodegenerative disease.
Meta-analysis demonstrated apigenin significantly reduced pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and NF-kB signaling pathway activation across multiple inflammation models.
Rahimi A, Alimohammadi M, Faramarzi F et al.. The effects of apigenin administration on the inhibition of inflammatory responses and oxidative stress in the lung injury models: a systematic review and meta-analysis of preclinical evidence. Inflammopharmacology. 2022
Balkrishna A, Rana M, Mishra S et al.. Exploring the therapeutic potential of phytochemicals apigenin and ellagic acid in managing polycystic ovarian syndrome and its comorbidities: a comprehensive review. Frontiers in endocrinology. 2025
Dietary apigenin intake positively correlates with sleep quality; apigenin improves memory, reduces tumor proliferation, and induces sedative effects in preclinical models.
Apigenin crosses the blood-brain barrier; its antioxidative, anti-inflammatory, neurogenic, and neuroprotective effects make it promising for neurodegenerative disorders.
Wang M, Firrman J, Liu L et al.. A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota. BioMed research international. 2019
Apigenin suppresses various human cancers by triggering apoptosis, inducing cell cycle arrest, suppressing migration/invasion, and stimulating immune response.
Tang D, Chen K, Huang L et al.. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert opinion on drug metabolism & toxicology. 2017
Apigenin inhibits CD38 NAD+ase activity, increasing intracellular NAD+ and decreasing protein acetylation; in mice, elevates NAD+ levels.
Apigenin prolonged pentobarbital-induced sleep via chloride ion channel activation, similar to the GABA-A receptor agonist muscimol.
Apigenin is a ligand for central benzodiazepine receptors, exerting anxiolytic and slight sedative effects without muscle relaxant or anticonvulsant activity.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack